All News Novartis AG

Equities

NOVN

CH0012005267

Market Closed - Swiss Exchange Other stock markets 11:30:41 2024-05-31 am EDT			5-day change	1st Jan Change
93.17 ^CHF	+2.13%		+1.56%	+9.78%

May. 31	NOVARTIS AG : UBS reiterates its Buy rating	ZD
May. 31	European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NOVARTIS AG : UBS reiterates its Buy rating	May. 31	ZD
European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected	May. 31	MT
Swiss Market Index in the Green Amid US Rate Cut Optimism	May. 31	MT
NOVARTIS AG : Jefferies remains its Buy rating	May. 31	ZD
Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints	May. 31	MT
Novartis Says New Data Show Long-term Efficacy, Safety of Potential Urticaria Therapy	May. 31	MT
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study	May. 31	MT
Novartis : Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high risk node negative disease	May. 31	PU
Novartis: positive trial results in chronic myeloid leukemia	May. 31	CF
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study	May. 31	MT
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML	May. 31	GL
Novartis: efficacy of remibrutinib in urticaria -USC	May. 31	CF
Novartis' Chronic Spontaneous Urticaria Treatment Shows Long-term Efficacy in Late-stage Trial Data	May. 30	MT
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria	May. 30	GL
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria	May. 30	DJ
Goldman Sachs Starts Novartis With Buy Rating, $120 Price Target	May. 30	MT
Alembic Pharmaceuticals Gets US FDA Final Nod for Sacubitril and Valsartan Tablets	May. 30	MT
NOVARTIS AG : From Sell to buy Rating by Goldman Sachs	May. 30	ZD
Novartis: positive phase III results in C3G	May. 27	CF
Novartis: presented results for kidney disease	May. 27	CF